Form 4: ImmunityBio Director Barry J. Simon Sells Shares
Insider Transaction Report
Director Barry J. Simon sold 23,033 shares of ImmunityBio, Inc. common stock via a pre-arranged 10b5-1 trading plan.
Summary
- Director Barry J. Simon sold 23,033 shares of ImmunityBio (IBRX) common stock.
- The transaction occurred on June 4, 2026, at a weighted average price of $7.1769 per share.
- The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2025.
- Following the transaction, the reporting person retains beneficial ownership of 2,827,788 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 arrangement, which is standard practice for directors.
Positives
- The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without triggering concerns regarding non-public information.
Negatives
- Insider selling can sometimes be perceived by the market as a lack of confidence in the short-term price appreciation of the stock.
Risks
- The reporting person's reduced equity stake may slightly decrease their alignment with common shareholders, though they remain a significant holder.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice in the biotechnology sector, often used by executives and directors to manage personal liquidity without signaling negative sentiment regarding company performance.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate insiders to ensure compliance with SEC regulations while liquidating equity positions.
Stakeholder Impact
- Minimal impact on shareholders as the sale was pre-planned and represents a small fraction of the director's total holdings.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 2025-12-18 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-06-04 | Date of the reported stock sale transaction. |
| 2026-06-05 | Date the Form 4 was signed and filed. |
Keywords
ImmunityBio, IBRX, Insider Trading, Form 4, Director Sale, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.